Rxivist logo

The Omicron variant of SARS-CoV-2 is raising concerns because of its increased transmissibility and potential for reduced susceptibility to antibody neutralization. To assess the potential risk of this variant to existing vaccines, serum samples from mRNA-1273 vaccine recipients were tested for neutralizing activity against Omicron and compared to neutralization titers against D614G and Beta in live virus and pseudovirus assays. Omicron was 41-84-fold less sensitive to neutralization than D614G and 5.3-7.4-fold less sensitive than Beta when assayed with serum samples obtained 4 weeks after 2 standard inoculations with 100 g mRNA-1273. A 50 g boost increased Omicron neutralization titers and may substantially reduce the risk of symptomatic vaccine breakthrough infections.

Download data

  • Downloaded 28,622 times
  • Download rankings, all-time:
    • Site-wide: 348
    • In infectious diseases: 133
  • Year to date:
    • Site-wide: 153
  • Since beginning of last month:
    • Site-wide: 395

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide